AVENuE : Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Treatment<br/>TrialTypeTreatment
Trial

TwoPhase Two

16-60Age 16-60

Blood<br/>CancersCancer LocationBlood
Cancers

Treatment | Blood / Myeloma / LymphomaHodgkin's Disease (Hodgkin's Lymphoma),Lymphoma

Trial Overview Read MoreRead more

This trial aims to assess the safety and effectiveness of avelumab, a targeted therapy, in patients that are previously untreated for high risk stage 2, stage 3 and stage 4 Hodgkin lymphoma .
 

This trial is treating patients with Hodgkin Lymphoma.

This is a systemic therapy.

You may be able to join this trial if:

  • You are currently receiving treatment for your cancer.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study

Commercial Sponsor

Pfizer

Other Non-Commercial Sponsor

University College, London

Summary

Eligible patients with newly diagnosed cHL will receive single agent avelumab in 2 cycles. Patients with newly diagnosed cHL will receive 4 doses of single agent avelumab intravenously, every 2 weeks.

Recruiting Hospitals Read MoreRead more

Austin Health
Heidelberg
Ms Samantha Chakar
samantha.chakar@austin.org.au
03 9496 3088

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next